Navigation Links
Masimo Pronto-7™ Receives Japanese and Canadian Regulatory Clearances
Date:8/29/2011

IRVINE, Calif., Aug. 29, 2011 /PRNewswire/ -- Masimo (NASDAQ: MASI) today announced the Japanese Ministry of Health Labor & Welfare (MHLW) and Health Canada regulatory clearances of Masimo Pronto-7™— enabling clinicians throughout Japan and Canada to quickly and conveniently measure total hemoglobin (SpHb®), SpO2, perfusion index, and pulse rate without removing a drop of blood.

Hemoglobin is one of the most commonly ordered tests in both the hospital and pre-hospital settings because it is critical to assessing blood loss following trauma, during surgery, and during hospital stay, as well as a patient's need for a blood transfusion. However, traditional lab testing requires a painful needle stick for the patient, time-consuming blood draws for the clinician, and typically provides delayed results. Masimo SpHb provides immediate real-time hemoglobin results that enable clinicians to more rapidly assess patients and detect and treat internal bleeding and low hemoglobin conditions earlier.  And, although Masimo noninvasive and continuous total hemoglobin (SpHb) monitoring—commercially available in both Japan and Canada for over a year—is the preferred technology for hospitals and inpatient care centers, access to quick and easy spot-check hemoglobin measurements are valuable for a variety of healthcare assessment applications, including physician offices, outpatient care centers, and pre-hospital emergency settings.  

Pronto-7 Makes Noninvasive Hemoglobin Testing a Reality in Japan and Canada

Japanese and Canadian regulatory clearances for the palm-sized, handheld Pronto-7 and noninvasive finger sensors make it possible for clinicians to take the pain and wait out of traditional hemoglobin blood testing.  The Pronto-7 offers a breakthrough solution for measuring tot
'/>"/>

SOURCE Masimo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns
2. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
3. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
4. New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
5. Masimo to Report Third Quarter 2009 Financial Results on November 3, 2009
6. New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology
7. New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the Blood
8. CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
9. St.Vincent Hospital Renews Multi-Year, System-wide Contract for Masimo SET(R) Pulse Oximetry Technology
10. Masimo Expands its Irvine, California Corporate Headquarters to Accommodate Growth Projections
11. Masimo to Present at the 28th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 NxStage Medical, ... of innovative dialysis products, announced today that the ... its System One™ to perform hemodialysis overnight while ... home nocturnal hemodialysis. NxStage,s® System One is the ... FDA for this indication. Home ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ... "Investment Analysis of the US Medical Device Sector ... http://photos.prnewswire.com/prnh/20130307/600769 This ... sector identifies the key trends and rationale for ... mergers and acquisitions. The study will ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Study Suggests That Ekkyo,s New Approach of LASH ... can Drastically Improve Scar Healing Physiology, MARSEILLES, ... Technology) a photomedicine company, which develops first-in-class,laser-based systems ... publication of a scientific article in Lasers in ...
... M.D., president of SPRI,Clinical Trials, will be a featured ... Group Investor Seminar -- Management,s Guide to,Wall Street. The ... Midtown,Loft & Terrace, 267 Fifth Avenue in New York. ... and small and mid-cap life science companies to gain,better ...
Cached Medicine Technology:Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife ... 700 smiling little faces this holiday that might not ... monetary donations was given to the various charities as ... incur through the year. Some of the charities chosen ... , Shrine's Children's Hospitals, Toys for Tots and Crisis ...
(Date:12/24/2014)... Rosa, CA (PRWEB) December 24, 2014 New ... particularly susceptible to hearing loss related depression (March 6, 2014, ... associated with gradual hearing loss (about 50 percent according to ... extremely positive effect on how a person feels and relates ... report that overall improvements are also made by way of:, ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. Stivarga is a drug which is used in ... is orally administered and is also prescribed to patients ... which is FDA approved is a multi-kinase inhibitor and ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... intra-aortic balloon pumps prior to angioplasty in patients with ... of heart muscle damage, a condition referred to as ... Duke University Medical Center researchers. The findings ... the American Medical Association ( JAMA ), and ...
... , MONDAY, Aug. 29 (HealthDay News) -- Although older ... may not be making good decisions about their coverage, ... -- particularly those with impaired brain function -- can ... plans available to them, preventing them from finding the ...
... , MONDAY, Aug. 29 (HealthDay News) -- The width ... performs, according to a new study. Researchers compared the ... their companies, financial performance. The study included only men because ... behavior applies only to men. The firms of CEOs ...
... agree that financial constraints and an aging population will require ... find that pushing back the eligibility age could be a ... most. The consequences both positive and negative of ... presented in the latest installment of the Public Policy & ...
... Caution is required when deciding whether to stop life support ... Researchers examined death rates after life support was ... brain injury in six trauma centers in the Canadian provinces ... the patients died in hospital, but the rate varied from ...
... EMPHASIS-HF study showed significant reductions in death and hospitalization ... failure (CHF) and mild symptoms treated with eplerenone in ... and standard therapy. Commenting on the findings presented ... Cardiology Congress (ESC) Hot Line Session on 29th August ...
Cached Medicine News:Health News:Study shows balloon pump use prior to angioplasty does not reduce heart muscle damage 2Health News:Some Older Americans Overwhelmed by Medicare Options, Study Says 2Health News:Some Older Americans Overwhelmed by Medicare Options, Study Says 3Health News:Aging authorities differ on tweaks to Social Security's benefit structure 2Health News:Use Caution in Ending Life Support for Brain-Injured, Experts Say 2Health News:The effect of eplerenone vs. placebo on cardiovascular mortality 2Health News:The effect of eplerenone vs. placebo on cardiovascular mortality 3
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
VascoStim B 2/5F is a bipolar temporary pacing lead with a balloon. It can be placed easily by the resistance of the inflated balloon in the blood flow....
Medicine Products: